NCT02342639View on ClinicalTrials.gov

Rifaximin Therapy in Chronic Kidney Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Chronic Kidney Disease
Interventions
DRUG

Rifaximin

550mg pills

DRUG

Placebo

Placebo pill

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

Jason Stubbs, MD

OTHER

NCT02342639 - Rifaximin Therapy in Chronic Kidney Disease | Biotech Hunter | Biotech Hunter